Simplify Logo

Full-Time

Head of DNA

Posted on 6/3/2024

Asimov

Asimov

51-200 employees

Integrated platform for genetic design and engineering

Hardware
AI & Machine Learning
Biotechnology
Healthcare

Expert

Boston, MA, USA

Category
Genomics
Biology & Biotech
Requirements
  • Ph.D. in Cell Biology, Molecular Biology, Bioengineering, Biotechnology, or related field
  • 5+ years of people management
  • 10+ years of DNA assembly or related molecular biology experience at a biopharma company or CDMO
Responsibilities
  • Establish a fast, reliable, and efficient resource for plasmid DNA assembly and QC release
  • Manage a team of scientists, research associates, and project managers
  • Maintain, deploy, and direct continuous development of robust high-throughput and automation-based DNA production workflows

Asimov offers a conducive environment for professionals passionate about genetic engineering, providing an integrated platform that includes engineered host cells, a genetic parts library, and advanced cloud-based design software. The company excels in the biotechnology field with its expertise in rationally-designed vectors, transposase-mediated integration, and scalable production of viral vectors, positioning it as a leader in biologics and gene therapies development. This focus on cutting-edge technology and substantial industry contributions makes it an ideal workplace for innovation-driven individuals.

Company Stage

Series B

Total Funding

$204.7M

Headquarters

Boston, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

0%

1 year growth

23%

2 year growth

86%
Simplify Jobs

Simplify's Take

What believers are saying

  • The launch of the LV Edge Producer System promises scalable, reproducible, and low-cost production of lentivirus, potentially unlocking larger therapeutic applications.
  • The establishment of Asimov Labs with The Foundry team enhances Asimov's R&D capabilities, driving forward advanced genetic design and engineering.
  • Asimov's innovative approach to synthetic biology and biocomputing could lead to significant breakthroughs in therapeutic development and manufacturing.

What critics are saying

  • The complexity of integrating The Foundry's team and infrastructure into Asimov could pose operational challenges.
  • The reliance on advanced genetic and computational tools may require substantial ongoing investment in R&D, impacting financial stability.

What makes Asimov unique

  • Asimov's LV Edge System offers a unique fully stable cell line development service, eliminating GMP plasmid costs and reducing process complexity, unlike traditional multi-plasmid transfection methods.
  • The integration of The Foundry's advanced genetic design capabilities from MIT and the Broad Institute positions Asimov at the forefront of genetic engineering innovation.
  • Asimov's focus on combining cellular, genetic, and computational tools to enable next-generation therapeutics sets it apart from competitors who may specialize in only one of these areas.
INACTIVE